ES2650375T5 - Probiotics for use in reducing symptoms of respiratory disease - Google Patents

Probiotics for use in reducing symptoms of respiratory disease Download PDF

Info

Publication number
ES2650375T5
ES2650375T5 ES14186663T ES14186663T ES2650375T5 ES 2650375 T5 ES2650375 T5 ES 2650375T5 ES 14186663 T ES14186663 T ES 14186663T ES 14186663 T ES14186663 T ES 14186663T ES 2650375 T5 ES2650375 T5 ES 2650375T5
Authority
ES
Spain
Prior art keywords
symptoms
culture
child
group
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14186663T
Other languages
English (en)
Spanish (es)
Other versions
ES2650375T3 (es
Inventor
Gregory Leyer
Arthur Ouwehand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International N&H Denmark ApS
Original Assignee
International N&H Denmark ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2650375(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by International N&H Denmark ApS filed Critical International N&H Denmark ApS
Publication of ES2650375T3 publication Critical patent/ES2650375T3/es
Application granted granted Critical
Publication of ES2650375T5 publication Critical patent/ES2650375T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES14186663T 2006-10-02 2007-09-14 Probiotics for use in reducing symptoms of respiratory disease Active ES2650375T5 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84866206P 2006-10-02 2006-10-02
US848662P 2006-10-02

Publications (2)

Publication Number Publication Date
ES2650375T3 ES2650375T3 (es) 2018-01-18
ES2650375T5 true ES2650375T5 (en) 2025-02-03

Family

ID=39268947

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14186663T Active ES2650375T5 (en) 2006-10-02 2007-09-14 Probiotics for use in reducing symptoms of respiratory disease
ES07838266.0T Active ES2547480T3 (es) 2006-10-02 2007-09-14 Lactobacillus acidophilus para su uso en reducir la incidencia y duración de infecciones respiratorias

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07838266.0T Active ES2547480T3 (es) 2006-10-02 2007-09-14 Lactobacillus acidophilus para su uso en reducir la incidencia y duración de infecciones respiratorias

Country Status (13)

Country Link
US (5) US20100040579A1 (enExample)
EP (2) EP2839836B2 (enExample)
JP (3) JP5896589B2 (enExample)
KR (2) KR101474188B1 (enExample)
CN (1) CN101528244B (enExample)
AU (1) AU2007302715B2 (enExample)
BR (1) BRPI0719787A2 (enExample)
DK (2) DK2068899T3 (enExample)
ES (2) ES2650375T5 (enExample)
FI (1) FI2839836T4 (enExample)
MX (1) MX2009003260A (enExample)
PL (2) PL2068899T3 (enExample)
WO (1) WO2008042101A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2835860B1 (en) 2009-12-02 2018-03-07 KMW Inc. Device selection structure
JP5885287B2 (ja) * 2010-09-02 2016-03-15 アサヒカルピスウェルネス株式会社 インフルエンザの予防および／または治療剤
CN103220921B (zh) * 2010-10-15 2015-12-16 科.汉森有限公司 免疫佐剂
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
ES2856013T3 (es) 2013-11-15 2021-09-27 Nestle Sa Composiciones para su uso en la prevención o tratamiento de infecciones del TRS en bebés o niños jóvenes en riesgo
CN103798392B (zh) * 2014-03-07 2015-12-30 内蒙古伊利实业集团股份有限公司 具有缓解咽喉部炎症功效的益生菌食品组合物及食品
MX380540B (es) 2015-03-05 2025-03-12 Soc Des Produits Nestle S A Star Composiciones para uso en la prevención o el tratamiento de otitis o bronquitis en infantes o niños pequeños.
WO2020170982A1 (ja) 2019-02-21 2020-08-27 オリンパス株式会社 フローラ治療用留置体、フローラ治療法
WO2021062250A1 (en) 2019-09-25 2021-04-01 Tall Goods, Llc Methods for producing probiotics fortified avian eggs and egg products and formulations thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007A (en) * 1845-04-22 Improvement in separating tannin and coloring-matter in quercitron-bark
DE69737420T2 (de) * 1996-11-29 2007-11-15 Bio K + International Inc., Montreal Milchsaüreferment das ein spezieller stamm von lactobacillus acidophilus enthältund verwendung
JP4212838B2 (ja) * 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
OA13142A (en) 2002-10-11 2006-12-13 Wyeth Corp Nutritional formulations containing synbiotic substances.
US20090257993A1 (en) * 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
DE102004026706A1 (de) * 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
WO2006088923A2 (en) * 2005-02-15 2006-08-24 Gorbach Sherwood L A food containing a probiotic and an isolated beta-glucan and methods of use thereof
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
KR101300086B1 (ko) 2005-10-06 2013-08-30 프로비 아베 자가면역질환의 치료를 위한 락토바실러스의 용도

Also Published As

Publication number Publication date
KR20140002069A (ko) 2014-01-07
DK2068899T3 (da) 2015-09-28
JP2010505824A (ja) 2010-02-25
PL2839836T3 (pl) 2018-02-28
KR101485200B1 (ko) 2015-01-26
CN101528244A (zh) 2009-09-09
US20140356329A1 (en) 2014-12-04
JP2014058558A (ja) 2014-04-03
PL2839836T5 (pl) 2025-11-17
DK2839836T4 (da) 2024-08-26
MX2009003260A (es) 2009-05-11
WO2008042101A3 (en) 2009-04-09
US20230256037A1 (en) 2023-08-17
FI2839836T4 (fi) 2024-08-26
AU2007302715B2 (en) 2013-01-31
DK2839836T3 (en) 2017-12-04
EP2068899A2 (en) 2009-06-17
AU2007302715A1 (en) 2008-04-10
EP2839836B2 (en) 2024-06-26
EP2839836B1 (en) 2017-08-30
US20100040579A1 (en) 2010-02-18
CN101528244B (zh) 2012-01-11
JP5896589B2 (ja) 2016-03-30
BRPI0719787A2 (pt) 2014-11-25
PL2068899T3 (pl) 2015-12-31
US20180000875A1 (en) 2018-01-04
US20200316145A1 (en) 2020-10-08
ES2650375T3 (es) 2018-01-18
KR101474188B1 (ko) 2014-12-17
EP2839836A1 (en) 2015-02-25
ES2547480T3 (es) 2015-10-06
KR20090063222A (ko) 2009-06-17
JP2016128478A (ja) 2016-07-14
WO2008042101A2 (en) 2008-04-10
EP2068899B1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
US20230256037A1 (en) Probiotics for use in reducing the incidence and duration of illness
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
Saavedra et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety
Jamalkandi et al. Oral and nasal probiotic administration for the prevention and alleviation of allergic diseases, asthma and chronic obstructive pulmonary disease
Maldonado et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants
Hojsak et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial
Lin et al. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study
ES2399775T3 (es) Composiciones farmacéuticas que comprenden L. acidophilus y bifidobacterium lactis para el uso en el tratamiento de un trastorno intestinal funcional
EP3823649A1 (en) Compositions comprising bacterial strains
ES2400187T3 (es) Bacterias lácticas y su uso en la prevención de la diarrea
WO2023085391A1 (ja) 風邪様症状の改善のための組成物
AU2013201783B2 (en) Probiotics for use in reducing the incidence and duration of illness
Lehtoranta Probiotics and immune modulation: reducing risk for cold and flu
Kloster Smerud et al. Effect of a probiotic milk product on gastrointestinal and respiratory infections in children attending day-care
Méndez-Malagón et al. Role of probiotics in the management of respiratory infections
Roper et al. The Use of Probiotics to Prevent Ventilator-Associated Pneumonia in Adults
Maldonado Lozano et al. Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial
Avadhani Probiotics: Review of evidenc
Fairbrother Advancing your practice: The power of probiotics
Fairbrother The power of probiotics.
Desland et al. Commonly Asked Questions about Probiotics and the Potential Benefits for Your Health: MB005/MB005, 12/2011
Mittal EFFECT OF PROBIOTICS ON TEETHING PROBLEMS IN INFANTS/TODDLERS
Thompson Probiotics may be effective for infantile colic